EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, NAVB: Navidea Biopharmaceuticals Inc

01 Oct 2025
LAST:

0.0001

CHANGE:
 0.00		OPEN:
0.0001		HIGH:
0.0002		ASK:
0.0000		VOLUME:
27.2K
CHG(%):
0.00		PREV:
0.0001		LOW:
0.0001		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
01 Oct 250.00010.00020.00010.000127.2K
30 Sep 250.00010.00010.00010.0001600
29 Sep 250.00020.00020.00020.0002400
26 Sep 250.00020.00020.00020.00021.2K
25 Sep 250.00020.00020.00020.00025.3K
24 Sep 250.00010.00010.00010.00016.6K
22 Sep 250.00010.00010.00010.0001300
19 Sep 250.00010.00010.00010.00015K
18 Sep 250.00010.00010.00010.00012.7K
17 Sep 250.00010.00010.00010.0001300

COMPANY PROFILE

Name:Navidea Biopharmaceuticals Inc
About:Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio. On October 1, 2025, Navidea Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Sector:Healthcare
Industry:Biotechnology
Address:4995 Bradenton Avenue, Dublin, OH, United States, 43017-3552
Website:https://www.navidea.com
CUSIP:63937X202
CIK:0000810509
ISIN:US63937X2027
FIGI:BBG000BCHXK7
LEI:549300HXUMV6VNCPEE05

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.00100.0%
MA10:0.000.0%
MA20:0.00200.0%
MA50:0.00300.0%
MA100:0.001,100.0%
MA200:0.00800.0%
RSI14:16.67 
WPR14:-100.00 
MTM14:0.00
ROC14:-0.80 
Week High:0.00100.0%
Week Low:0.000.0%
Month High:0.00400.0%
Month Low:0.00800.0%
Year High:0.0549,900.0%
Year Low:0.000.0%
Volatility:438.88